caa a22 4500 477072313 CHVBK 20180405111429.0 cr unu---uuuuu 170330e19961101xx s 000 0 eng 10.1007/BF00052511 doi (NATIONALLICENCE)springer-10.1007/BF00052511 Cardioprotective effect of angiotensin-converting enzyme inhibitors in patients with coronary artery disease [Elektronische Daten] [R. Ferrari, C. Ceconi, S. Curello, P. Pepi, A. Mazzoletti, O. Visioli] Summary: Clinical and experiments study with angiotensin-converting enzyme (ACE) inhibitors suggest that these agents may improve coronary artery disease by acting at multiple sites in the series of events leading to end-stage heart disease. These agents reduce blood pressure, improve prognosis and symptoms in patients with severe heart failure and in patients after acute myocardial infarction with left ventricular dysfunction. They are useful in the early, acute phase of myocardial infarction. More recently, ACE inhibitors have been shown to reduce in vitro vascular hypertrophy, to attenuate arteriosclerosis, and to maintain endothelium function. Whether these effects occur at clinical levels is still uncertain. The exciting clinical data have led to the proposal that alteration of ACE activity, particularly in tissue, is an important factor in development and progression of CAD. The ACE system is complex, with endocrine, paracrine, and autocrine effects. ACE is present in cardiac and vascular tissue. Therefore, the beneficial effects of ACE inhibitors can be classified as "cardio” and "vasculo” protective. This article summarizes a number of independent and complementary mechanisms pointing to a role of ACE and ACE inhibition in coronary artery disease. Kluwer Academic Publishers, 1996 angiotensin-converting enzyme nationallicence coronary artery disease nationallicence enalapril nationallicence captopril nationallicence quinapril nationallicence cardiac protection nationallicence Ferrari R. Cardiovascular Pathophysiology Research Center, University of Brescia, "Salvatore Maugeri” Foundation, IRCCS, Gussago, Brescia, Italy aut Ceconi C. Cardiovascular Pathophysiology Research Center, University of Brescia, "Salvatore Maugeri” Foundation, IRCCS, Gussago, Brescia, Italy aut Curello S. Cardiovascular Pathophysiology Research Center, University of Brescia, "Salvatore Maugeri” Foundation, IRCCS, Gussago, Brescia, Italy aut Pepi P. Cardiovascular Pathophysiology Research Center, University of Brescia, "Salvatore Maugeri” Foundation, IRCCS, Gussago, Brescia, Italy aut Mazzoletti A. Cardiovascular Pathophysiology Research Center, University of Brescia, "Salvatore Maugeri” Foundation, IRCCS, Gussago, Brescia, Italy aut Visioli O. Cardiovascular Pathophysiology Research Center, University of Brescia, "Salvatore Maugeri” Foundation, IRCCS, Gussago, Brescia, Italy aut Cardiovascular Drugs and Therapy Kluwer Academic Publishers 10(1996-11-01), 639-647 0920-3206 10<639 1996 10 10557 https://doi.org/10.1007/BF00052511 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF00052511 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Ferrari R. Cardiovascular Pathophysiology Research Center, University of Brescia, "Salvatore Maugeri” Foundation, IRCCS, Gussago, Brescia, Italy aut NATIONALLICENCE 700 1- Ceconi C. Cardiovascular Pathophysiology Research Center, University of Brescia, "Salvatore Maugeri” Foundation, IRCCS, Gussago, Brescia, Italy aut NATIONALLICENCE 700 1- Curello S. Cardiovascular Pathophysiology Research Center, University of Brescia, "Salvatore Maugeri” Foundation, IRCCS, Gussago, Brescia, Italy aut NATIONALLICENCE 700 1- Pepi P. Cardiovascular Pathophysiology Research Center, University of Brescia, "Salvatore Maugeri” Foundation, IRCCS, Gussago, Brescia, Italy aut NATIONALLICENCE 700 1- Mazzoletti A. Cardiovascular Pathophysiology Research Center, University of Brescia, "Salvatore Maugeri” Foundation, IRCCS, Gussago, Brescia, Italy aut NATIONALLICENCE 700 1- Visioli O. Cardiovascular Pathophysiology Research Center, University of Brescia, "Salvatore Maugeri” Foundation, IRCCS, Gussago, Brescia, Italy aut NATIONALLICENCE 773 0- Cardiovascular Drugs and Therapy Kluwer Academic Publishers 10(1996-11-01), 639-647 0920-3206 10<639 1996 10 10557 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer